<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712034</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1418</org_study_id>
    <secondary_id>1R01DA040449-01</secondary_id>
    <nct_id>NCT02712034</nct_id>
  </id_info>
  <brief_title>Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth</brief_title>
  <acronym>Bundling</acronym>
  <official_title>Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Street Treatment and Resources (SSTAR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gosnold on Cape Cod</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARC Community Services, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to measure and explain the impact on long-term opioid use
      when medication-assisted treatment (MAT) is bundled with an evidence-based mobile-health
      system (A-CHESS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid use</measure>
    <time_frame>24 months</time_frame>
    <description>Detect the difference in illicit opioid use between patients who have MAT + A-CHESS vs. MAT alone.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Opioid Use Disorder</condition>
  <arm_group>
    <arm_group_label>Medication-assisted treatment (MAT)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive standard medication-assisted treatment (MAT) as prescribed by their health care provider.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAT + A-CHESS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the MAT + A-CHESS arm will receive MAT as described plus the A-CHESS recovery support system via a smartphone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MAT + A-CHESS</intervention_name>
    <description>Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:
Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.
The latest information about addiction and recovery support, monitoring prompts, and peer and family support.
Advice on where to go for help and on how to make the best use of health and human services; and
A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.
A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects).</description>
    <arm_group_label>MAT + A-CHESS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MAT</intervention_name>
    <description>Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. &quot;Appropriate pharmacology&quot; may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care.</description>
    <arm_group_label>Medication-assisted treatment (MAT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. are 18+ years old;

          2. meet criteria for opioid use disorders of at least moderate severity (4 or 5 DSM-V
             criteria);

          3. Are currently taking medication-assisted treatment (MAT) as part of their standard
             clinical care;

          4. have no acute medical problem requiring immediate inpatient treatment;

          5. have no history of psychotic disorders, though those with other co-morbid
             psychopathology (mood disorders, anxiety, other substance use disorders) will be
             eligible;

          6. are willing to participate in a randomized clinical trial;

          7. provide the name, verified telephone number, and address of at least 2 contacts
             willing to help locate the patient, if necessary, during follow-up;

          8. are able to read and write in English;

          9. are not pregnant;

         10. are willing to share health-related data with primary care clinicians; and

         11. are, at study intake, abstinent from opioids for at least 1 week and no longer than 2
             months, except for medications used to treat the disorder (e.g., methadone).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H Gustafson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gina M Landucci, BS</last_name>
    <phone>1-800-361-5481</phone>
    <email>gina.landucci@wisc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Access Community Health Centers</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medication-assisted treatment (MAT)</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Methadone</keyword>
  <keyword>Naltrexone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

